Multiple Sclerosis News

Stem Cells Used to Treat Secondary Progressive Patients in Clinical Trial

What may work better than existing drugs to treat severe multiple sclerosis? Stem cells. A phase 2 clinical study from an international group of research centers compared head-to-head autologous hematopoietic stem cell transplantation (AHSCT) and mitoxantrone in treating patients with secondary progressive or relapsing-remitting multiple sclerosis. The findings showed that…

Creative Medical Seeks Patent for Stem Cell Therapy for MS

Phoenix, Arizona-basedĀ Creative Medical Health (CMH) has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The companyĀ is already preparing to launch the product into its first line of clinical tests, which will…

Novel Antibody Drug Candidate From Chinese Drug Developer Shows Promise For Treating MS

MicroConstants China, Inc., a company thatĀ provides preclinical, clinical, and consulting services to biotechnology and pharmaceutical companies, has just announced it has acquired international rights to the development of AA98 antibody pipeline products, indicated for the treatment of several types of cancer, multiple sclerosis,Ā and age related macular degeneration…

Phase I Clinical Studies To Begin Using Anatabine Citrate as Possible Therapy For MS

Drug development companyĀ Rock Creek Pharmaceuticals, Inc.Ā recently announced that a newĀ clinical trial application with theĀ United Kingdom’sĀ Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of its flagship pipeline product, Anatabine Citrate,Ā a chemical that is found naturally…

Amarantus Acquires DioGenix to Bolster New MS Diagnostic Division

Amarantus BioScience Holdings, Inc. has announced the acquisition ofĀ DioGenix, Inc., which will be merged asĀ a newĀ foundational asset intoĀ a growing neuro-diagnostic division at AmarantusĀ calledĀ Amarantus Diagnostics. Amarantus BioScience isĀ dedicated to developing novel neurological diagnostic tests and therapy options in the fields ofĀ neurology, psychiatry, ophthalmology and regenerative diseases, including multiple…

Researchers Study Device to Improve Balance for MS Patients

Multiple sclerosis (MS) patients often experience difficultyĀ with balance and fear falling, which may prevent themĀ from being social or participating in exercise and community activities, affecting their quality of life. However, a pioneering study conducted atĀ the University of Massachusetts Amherst is looking to understand the role of…

Plegridy for Relapsing MS Now Approved in Scotland

The Scottish Medicines Consortium has just approved Biogen Idec’sĀ Plegridy (peg interferonĀ beta-1a) for the treatment of relapsing multiple sclerosis (MS) in patients between 18 to 65 years old, making the Consortium the first United Kingdom-based regulatory body to endorse the disease-modifying drug on the…

A Step Toward Multiple Sclerosis Treatment? Phase 2 ANTI-LINGO-1 Results Announced

Biogen Idec, a Cambridge Massachusetts Biotechnology company,Ā has released results from itsĀ Phase 2 acute optic neuritis (AON) RENEW trial. The trial testedĀ anti-LINGO-1, a medication that restores myelin — a fatty substance that facilitates nerve cell impulses by wrapping around them and providing insulation. The trial results indicateĀ that anti-LINGO-1…

Multiple Sclerosis Risk Does not Increase with HPV Vaccine According to Study

Human papillomavirus (HPV) vaccination can help protect against several health problems, including cervical cancers in women. Some reports have raised concerns however, that the vaccine might actually increase the risk of developing multiple sclerosis. A studyĀ entitled “Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other…

RRMS Study Using MRI Reveals Benefits of Experimental Therapy in Achieving No Evidence of Disease Activity

Results from aĀ Phase 3 clinical trial entitled “AVANCE” revealed promising clinical outcomes in patients with relapsing-remitting multiple sclerosis treated forĀ one year with peg interferon beta-1a. The analysis wasĀ published in the journal BMC Neurology, in a study entitled ā€œEffect of peg interferon beta-1a on MRI measures and…

Top 14 Multiple Sclerosis Stories of ’14

Given the fact that MS isĀ aĀ chronic, progressive, and disabling disease for which there is no cure, the multiple sclerosis community is always looking forward to the latestĀ news regarding new therapies, devices or scientific findings about treating and curing the disease. TheseĀ are the top 14 news stories of 2014 from…

New MS Study Seeks To Understand How Inflammation Causes Neuronal Damage in Multiple Sclerosis

A team of researchers from Italy recently examined if p53 genetic variants influence synaptic and toxic effects of cytokines in the neurodegenerative processes that occurs in Multiple Sclerosis. The study, entitled ā€œInterleukin-1Ī² causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53,ā€ was recently published…